---
title: 1% Treaty ROI Tiers - Detailed Analysis
description: Comprehensive breakdown of the Complete Case (1,222:1 ROI) showing all direct benefits from the 1% Treaty
published: true
jupyter: dih-project-kernel
tags:
  - 1-percent-treaty
  - roi-analysis
  - economic-analysis
  - cost-benefit
---

```{python}
#| echo: false
import sys
import os

# Quarto executes from project root (execute-dir: project in _quarto.yml)
appendix_path = os.path.join(os.getcwd(), 'brain', 'book', 'appendix')
if appendix_path not in sys.path:
    sys.path.insert(0, appendix_path)

from economic_parameters import *
```

## Overview

The [conservative `{python} format_roi(ROI_TIER_1_CONSERVATIVE)` ROI estimate](../economics/health-dividend.qmd) captures only the direct dFDA platform benefits. The **Complete Case** shows what happens when you count all direct benefits from the 1% Treaty system.

This analysis focuses on provable, quantifiable benefits with conservative assumptions. For the underlying calculations and NPV methodology, see [Health Dividend Calculations](health-dividend-calculations.qmd).

---

## The Complete Case: `{python} format_roi(ROI_TIER_2_COMPLETE)` ROI (All Direct Benefits)

The conservative `{python} format_roi(ROI_TIER_1_CONSERVATIVE)` calculation ignores most of what the 1% Treaty actually does. When you count everything:

### `{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)` in Annual Benefits

The 1% Treaty doesn't just make trials cheaper. It:

1. **Societal savings from 1% less conflict** (peace dividend: $97B)
2. **Slashes R&D costs `{python} TRIAL_COST_REDUCTION_FACTOR`x** (saves `{python} format_billions(DFDA_GROSS_SAVINGS_ANNUAL)`)
3. **Accelerates access by 7 years** (saves $300B via early trial access)
4. **115X more research capacity** (adds $100B via 10-20X more breakthroughs)
5. **Enables treatment of rare/orphan diseases** (adds $400B)
6. **Reduces drug prices via R&D savings** (saves `{python} format_billions(GLOBAL_CLINICAL_TRIAL_MARKET_ANNUAL)`)
7. **Makes prevention economically viable** (saves $100B)
8. **Addresses mental health treatment gap** (adds $75B)

Each of these alone is worth tens to hundreds of billions. Together? **`{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)`/year.**

---

## The 7-Year Access Acceleration

**The insight:** The dFDA gives patients the right and ability to access treatments during Phase 2/3 trials instead of waiting 9.1 years for FDA approval (or forever if trials are never completed for their condition).

**How it works:**
- Current system: Wait 9.1 years average from Phase 1 to FDA approval
- dFDA system: Access treatment during Phase 2/3 pragmatic trials
- Effective acceleration: ~7 years earlier access on average

**This isn't speculative future acceleration - it's immediate access to treatments that already exist but are stuck in the approval pipeline.**

### Stock Benefit (One-Time)

Existing patients get immediate access:
- 2 billion people with chronic diseases globally
- Each gains 7 years of treatment access they'd otherwise miss
- Total: 14 billion person-years × $150K/QALY = $2.1T total value
- **Amortized over 7-year acceleration period: $300B/year for years 1-7**

### Flow Benefit (Ongoing)

New patients each year get early access:
- ~100M new chronic disease cases/year globally
- Each saves 7 years × $150K/QALY = $1.05M in value
- **Annual flow: $105B/year ongoing (continues forever)**

### Combined Benefit

**Combined "earlier access" benefit:**
- Years 1-7: $300B (amortized stock) + $105B (flow) = **$405B/year**
- Years 8+: $105B/year (flow only)
- **10-year average: ~$300B/year**

---

## The Research Acceleration Multiplier

**The insight:** `{python} TRIAL_COST_REDUCTION_FACTOR`x cheaper trials + 40% more funding (`{python} format_billions(TREATY_ANNUAL_FUNDING)`/year) = **115X more research capacity**.

**What this means:**
- Current: ~3,300 clinical trials/year globally, ~50 new drug approvals/year
- New capacity: ~380,000 trials/year possible, ~1,000-2,000 approvals/year (20-40X increase)

**This is NOT the same as "earlier access":**
- **Earlier Access** = Accessing the SAME 50 drugs in pipeline 7 years sooner
- **Research Acceleration** = Testing 115X MORE drug candidates, finding 10-20X MORE breakthroughs

### Which Diseases Benefit

These are common diseases that are UNDER-researched because trials are too expensive:

- Chronic pain (1.5B people, very limited treatment options)
- Mental health (1B people, huge treatment gaps)
- Alzheimer's (55M people, almost nothing works)
- Autoimmune diseases (500M people, limited options)
- Long COVID (100M+, zero approved treatments)

These are NOT rare diseases (already counted). These are common diseases with limited treatment options due to insufficient research investment.

**Conservative annual value: $100B/year**

*Note: This is a conservative estimate based on health outcomes. For market valuation approaches suggesting substantially higher values ($6.48T/year with 80X acceleration), see [Economic Value of Accelerated Treatments](economic-value-of-accelerated-treatments.qmd).*

---

## The Complete Benefit Breakdown

| Category | Annual Benefit | Notes |
|----------|----------------|-------|
| [Peace Dividend](../economics/peace-dividend.qmd) | $97B | Societal savings from 1% reduction in global conflict |
| R&D Cost Savings | `{python} format_billions(DFDA_GROSS_SAVINGS_ANNUAL)` | `{python} TRIAL_COST_REDUCTION_FACTOR`x trial cost reduction |
| **Earlier Access (7 years)** | **$300B** | Existing pipeline accessed sooner |
| **Research Acceleration** | **`{python} format_billions(GLOBAL_CLINICAL_TRIAL_MARKET_ANNUAL)`** | 115X more trials = 10-20X more breakthroughs |
| New Diseases Treatable | $400B | Rare diseases, orphan drugs |
| Drug Price Reduction | `{python} format_billions(GLOBAL_CLINICAL_TRIAL_MARKET_ANNUAL)` | R&D savings passed to consumers |
| Prevention Medicine | $100B | Economic viability of prevention |
| Mental Health Impact | $75B | Treatment gap reduction |
| | | |
| **ECONOMIC TOTAL** | **$1.222 TRILLION/YEAR** | |

**ROI:** $1.222T / $1B investment = **`{python} format_roi(ROI_TIER_2_COMPLETE)`**

**Note:** Insurance savings, productivity gains, and longevity extension are outcomes of the above benefits and not counted separately to avoid double-counting.

---

## The Sanity Check

**Is `{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)`/year reasonable?**

- Global GDP: $111 trillion/year
- Global healthcare spending: $9.8 trillion/year
- Global military spending: $2.7 trillion/year

If the 1% Treaty generates `{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)`/year in benefits, that's:
- 1.1% of global GDP
- 12.4% of healthcare spending
- 45% of military spending

**This passes the smell test.**

For comparison:
- Eliminating all cancer: ~$1.1T/year economic value
- Curing all infectious disease: ~$800B/year
- Fixing mental health: ~$300B/year

The 1% Treaty doesn't cure everything, but it:
- Accelerates access by 7 years (earlier trial participation)
- Increases research velocity 10-20X (more breakthroughs)
- Enables trials for currently untreatable conditions

`{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)`/year is reasonable for that scope.

---

## Technical Notes

### Sources and Methodology

- **Trial cost reduction**: Based on [RECOVERY trial model](../references.qmd#recovery-trial-cost-reduction) achieving ~$500/patient vs traditional $40-120K/patient
- **Research capacity multiplier**: `{python} TRIAL_COST_REDUCTION_FACTOR`x cost reduction × 1.4X funding increase = 115X capacity
- **QALY valuations**: Standard [$100-150K per QALY](../references.qmd#qaly-value) methodology
- **Disease prevalence**: WHO global burden of disease data
- **Economic impact estimates**: See [dFDA Cost-Benefit Analysis](dfda-cost-benefit-analysis.qmd) for detailed calculations

### What's Not Included

To maintain conservative estimates, this analysis excludes:

- **Indirect economic benefits**: Productivity gains, reduced sick days, caregiver time savings
- **Longevity extension**: Additional life-years from better treatments
- **Quality of life improvements**: Beyond QALY calculations
- **Innovation spillovers**: Adjacent technology development, AI/ML advances
- **Compounding effects**: Year-over-year acceleration as system matures

Including these would push the ROI substantially higher, but they're harder to quantify with precision.

---

## Related Analysis

- **Conservative Case (`{python} format_roi(ROI_TIER_1_CONSERVATIVE)`)**: See [Health Dividend](../economics/health-dividend.qmd) for the baseline NPV-adjusted ROI
- **NPV Methodology**: See [Health Dividend Calculations](health-dividend-calculations.qmd) for 10-year NPV analysis with discount rates
- **Cost-Effectiveness**: See [1% Treaty Cost-Effectiveness](1-percent-treaty-cost-effectiveness.qmd) for ICER and cost-per-QALY analysis
- **Daily Opportunity Cost**: See [Daily Opportunity Cost](dfda-daily-opportunity-cost.qmd) for the cost of delay

---

## Bottom Line

The **Complete Case** shows that when you count all direct, quantifiable benefits from the 1% Treaty:

- **`{python} format_billions(TOTAL_COMPLETE_BENEFITS_ANNUAL)`/year in societal value**
- **`{python} format_roi(ROI_TIER_2_COMPLETE)` return on investment**
- **Benefits span immediate access acceleration, research capacity expansion, and systemic healthcare improvements**

This is the comprehensive picture of what the 1% Treaty delivers. For decision-making and public communication, we recommend the more conservative `{python} format_roi(ROI_TIER_1_CONSERVATIVE)` figure to maintain credibility, but the full scope of benefits is substantially larger.
